Biogen Pharmachem Industries Limited passed all three ordinary resolutions at its 31st Annual General Meeting held on September 29, 2026, via Video Conferencing, with voting results now submitted to the stock exchange under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting commenced at 4:00 pm and concluded at 4:20 pm. A total of 300,794 shareholders were on record as of the record date. Of these, 32 public shareholders attended via video conferencing, while no promoter or promoter group shareholders attended. All voting was conducted through e-voting by the public non-institutions category, as promoter and promoter group held zero shares.

Key resolutions passed

Shareholders approved three ordinary resolutions during the session:

• Adoption of the audited financial statements for FY26, along with the reports of the Directors and Auditors.
• Reappointment of Kelash Bunkar (DIN: 10911360) as a director retiring by rotation.
• Appointment of M/s. Goenka Mehta & Associates Chartered Accountants, Rajkot (Firm Registration No: 129445W), as statutory auditors and fixation of their remuneration.

Detailed voting results

All voting activity was recorded under the public non-institutions category via e-voting. The following tables detail the outcome for each resolution.

Resolution 1: Adoption of audited financial statements for FY26

Resolution 2: Reappointment of Kelash Bunkar as director

In both resolutions, the promoter and promoter group category as well as public institutions recorded zero shares held and zero votes polled. All participation came from the public non-institutions segment through e-voting.

Shareholder participation overview

The overall voter turnout across both resolutions stood at 5.254% of outstanding shares. Resolution 1 on financial statement adoption received the highest approval at 99.98% of votes polled in favour, while Resolution 2 on Bunkar's reappointment received 99.64% approval. The voting results were submitted to BSE Limited in the prescribed format as required under the applicable listing regulations.

Biogen Pharmachem Industries Limited reported a net profit of ₹85.95 lakh for the fiscal year ended March 31, 2026 (FY26), reversing a loss of ₹29.27 lakh in the previous year. The company has scheduled its 31st Annual General Meeting for Tuesday, September 29, 2026.

The entity, formerly known as Sun Techno Overseas Limited, generated total revenue of ₹255.80 lakh, derived entirely from other income as it had no operational revenue from its core business activities during the period.

Financial Performance

Biogen Pharmachem's financial results for FY26 highlight a shift to profitability driven by investment returns rather than operational turnover.

Other income surged to ₹255.80 lakh from ₹119.77 lakh in FY25. This increase was primarily driven by interest income of ₹193.51 lakh and capital gains of ₹59.89 lakh. The company recorded total expenses of ₹160.13 lakh, including employee benefit expenses of ₹28.28 lakh and other expenses of ₹131.85 lakh.

Balance Sheet and Assets

As of March 31, 2026, the company's total assets stood at ₹9,939.89 lakh, an increase from ₹9,201.77 lakh in the prior year. Non-current assets comprised the majority of the balance sheet, with investments valued at ₹3,278.23 lakh and long-term loans and advances amounting to ₹6,612.97 lakh.

Cash and cash equivalents decreased significantly to ₹32.16 lakh from ₹201.63 lakh in FY25. This reduction reflects cash outflows for investments and long-term advances, partially offset by proceeds of ₹630.00 lakh from the conversion of preferential warrants into equity shares.

Capital Structure

The issued, subscribed, and paid-up capital increased to ₹90,26.03 lakh, divided into 90,26,03,000 equity shares of ₹1 each. This rise followed the allotment of 25,00,00,000 fully convertible warrants into equity shares on a preferential basis to the non-promoter group on April 15, 2025.

Promoter holding remained at 0%. Significant shareholders holding more than 5% include Interface Financial Services Limited (9.31%), Parichay Infrastructure Limited (8.59%), and Rama Shiva Lease Finance Private Limited (8.26%).

Corporate Governance and AGM Details

The 31st AGM will be held through Video Conferencing or Other Audio Visual Means. Shareholders will vote on ordinary business items, including:

• Adoption of audited financial statements for FY26 along with Board and Auditor reports.
• Reappointment of Kelash Bunkar as a director retiring by rotation.
• Reappointment of M/s Goenka Mehta & Associates as statutory auditors until the AGM in 2031.

Remote e-voting will be available from Saturday, September 26, 2026, at 9:00 am to Monday, September 28, 2026, at 5:00 pm. The record date for voting rights is Tuesday, September 22, 2026.

What the Numbers Show

The company's profitability is entirely non-operational. With zero revenue from operations and total revenue comprising solely other income, the net profit of ₹85.95 lakh is driven by interest income and capital gains on investments. The significant drop in cash balances alongside an increase in long-term loans and investments suggests a strategic deployment of funds into financial assets rather than working capital for operational expansion.